198 related articles for article (PubMed ID: 1905530)
1. Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset.
Makowska JM; Bonner FW; Gibson GG
Arch Toxicol; 1991; 65(2):106-13. PubMed ID: 1905530
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
Makowska JM; Anders C; Goldfarb PS; Bonner F; Gibson GG
Biochem Pharmacol; 1990 Sep; 40(5):1083-93. PubMed ID: 2390105
[TBL] [Abstract][Full Text] [Related]
3. Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation.
Makowska JM; Gibson GG; Bonner FW
J Biochem Toxicol; 1992; 7(3):183-91. PubMed ID: 1282571
[TBL] [Abstract][Full Text] [Related]
4. Role of thyroid state on induction by ciprofibrate of laurate hydroxylase and peroxisomal enzymes in rat liver microsomes.
Pacot C; Charmoillaux M; Goudonnet H; Truchot RC; Latruffe N
Biochem Pharmacol; 1993 Apr; 45(7):1437-46. PubMed ID: 8471068
[TBL] [Abstract][Full Text] [Related]
5. Response of genetically obese Zucker rats to ciprofibrate, a hypolipidemic agent, with peroxisome proliferation activity as compared to Zucker lean and Sprague-Dawley rats.
Pacot C; Petit M; Caira F; Rollin M; Behechti N; Grégoire S; Cherkaoui Malki M; Cavatz C; Moisant M; Moreau C
Biol Cell; 1993; 77(1):27-35. PubMed ID: 8518742
[TBL] [Abstract][Full Text] [Related]
6. Characterization of ciprofibrate and clofibric acid as peroxisomal proliferators in primary cultures of rat hepatocytes.
Feller DR; Singh Y; Shirhatti VR; Kocarek TA; Liu CT; Krishna G
Hepatology; 1987; 7(3):508-16. PubMed ID: 3570161
[TBL] [Abstract][Full Text] [Related]
7. Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4-fluoro-substituted analogues in rat.
Graham MJ; Winham MA; Old SL; Gray TJ
Xenobiotica; 1996 Jul; 26(7):695-707. PubMed ID: 8819300
[TBL] [Abstract][Full Text] [Related]
8. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid.
Wilson MW; Lay LT; Chow CK; Tai HH; Robertson LW; Glauert HP
Arch Toxicol; 1995; 69(7):491-7. PubMed ID: 8526745
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver.
Lalwani ND; Reddy MK; Qureshi SA; Sirtori CR; Abiko Y; Reddy JK
Hum Toxicol; 1983 Jan; 2(1):27-48. PubMed ID: 6840792
[TBL] [Abstract][Full Text] [Related]
10. On the mechanism of induction of microsomal cytochrome P450IVA1 and peroxisome proliferation in rat liver by clofibrate.
Milton MN; Elcombe CR; Gibson GG
Biochem Pharmacol; 1990 Dec; 40(12):2727-32. PubMed ID: 2260995
[TBL] [Abstract][Full Text] [Related]
11. Effect of dexamethasone on ciprofibrate-induced cell proliferation and peroxisome proliferation.
Rao MS; Subbarao V
Fundam Appl Toxicol; 1997 Jan; 35(1):78-83. PubMed ID: 9024675
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes.
Cornu-Chagnon MC; Dupont H; Edgar A
Fundam Appl Toxicol; 1995 Jun; 26(1):63-74. PubMed ID: 7657063
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the concentrations of prostaglandins E2 and F2alpha, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate.
Leung LK; Glauert HP
Toxicol Lett; 1996 Jun; 85(3):143-9. PubMed ID: 8644126
[TBL] [Abstract][Full Text] [Related]
14. Stereochemical selectivity in the induction of cytochrome P450IVA1 (P452)-dependent fatty acid hydroxylation and peroxisome proliferation.
Chinje E; Gibson GG
Biochem Pharmacol; 1991 Mar; 41(5):769-74. PubMed ID: 1998531
[TBL] [Abstract][Full Text] [Related]
15. Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats.
Chen H; Huang CY; Wilson MW; Lay LT; Robertson LW; Chow CK; Glauert HP
Carcinogenesis; 1994 Dec; 15(12):2847-50. PubMed ID: 8001245
[TBL] [Abstract][Full Text] [Related]
16. Ciprofibrate--racemate and enantiomers: effects of a four-week treatment on male inbred Fischer rats. A biochemical and morphological study.
Klinger W; Lupp A; Karge E; Oelschläger H; Rothley D; Danz M; Linss W; Löbel S; Deufel T; Müller M; Klinger M; Kühnel W
Exp Toxicol Pathol; 1998 Sep; 50(4-6):301-14. PubMed ID: 9784002
[TBL] [Abstract][Full Text] [Related]
17. The effects of diquat and ciprofibrate on mRNA expression and catalytic activities of hepatic xenobiotic metabolizing and antioxidant enzymes in rat liver.
Gallagher EP; Buetler TM; Stapleton PL; Wang C; Stahl DL; Eaton DL
Toxicol Appl Pharmacol; 1995 Sep; 134(1):81-91. PubMed ID: 7676460
[TBL] [Abstract][Full Text] [Related]
18. Effect of the peroxisome proliferator ciprofibrate on hepatic cyclooxygenase and phospholipase A2 in rats.
Leung LK; Glauert HP
Toxicology; 1998 Feb; 126(1):65-73. PubMed ID: 9585093
[TBL] [Abstract][Full Text] [Related]
19. Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years.
Graham MJ; Wilson SA; Winham MA; Spencer AJ; Rees JA; Old SL; Bonner FW
Fundam Appl Toxicol; 1994 Jan; 22(1):58-64. PubMed ID: 8125214
[TBL] [Abstract][Full Text] [Related]
20. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
Rao MS; Dwivedi RS; Subbarao V; Reddy JK
Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
